id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0492-0006,FDA,FDA-2025-E-0492,Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-04-15T03:59:59Z,2026-02-13T19:36:15Z,2026-02973,1,0,09000064b91a9f1c
FDA-2025-E-0492-0005,FDA,FDA-2025-E-0492,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-12-03T05:00:00Z,2025,12,2025-12-03T05:00:00Z,,2025-12-03T20:20:10Z,,0,0,09000064b90aa54e
FDA-2025-E-0492-0004,FDA,FDA-2025-E-0492,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T22:17:05Z,,0,0,09000064b9069bb5
FDA-2025-E-0492-0003,FDA,FDA-2025-E-0492,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-10-10T04:00:00Z,2025,10,2025-10-10T04:00:00Z,,2025-10-10T22:32:20Z,,0,0,09000064b900703f
FDA-2025-E-0492-0002,FDA,FDA-2025-E-0492,"Patent Extension Application from Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. (on behalf of Neurocrine Biosciences, Inc.)",Other,Application,2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:34:16Z,,0,0,0900006486991f89
FDA-2025-E-0492-0001,FDA,FDA-2025-E-0492,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:32:10Z,,0,0,0900006486991f88